03 · What You Need to Know
Post-Trial Access Begins as a Pre-Trial Planning Problem
Post-trial access is not simply continued participation in research
During a trial, access to an experimental intervention occurs within a research protocol. Eligibility criteria, randomization, monitoring, data collection, safety reporting, study visits, and sponsor responsibilities govern that access.
When the trial ends, the research framework changes. Yet a participant may still have a clinical need for the intervention.
Post-trial access addresses the transition between those two circumstances. It asks what should happen when research access formally ends but continued access remains ethically relevant.
Access during the trial
The intervention is provided according to the research protocol while its safety, efficacy, or other outcomes are being investigated.
Post-trial access
Continued access after the trial for participants who still need an intervention that has been identified as beneficial and reasonably safe, according to applicable ethical arrangements.
The 2024 Declaration of Helsinki uses a specific standard
The current Declaration of Helsinki states that, before a clinical trial, sponsors and researchers must arrange post-trial provisions for all participants who still need an intervention identified as beneficial and reasonably safe in the trial.
Three parts of that formulation deserve attention.
First, the participant must still need the intervention. Post-trial access is not framed as automatic distribution to every person who enrolled.
Second, the intervention must have been identified as beneficial and reasonably safe in the trial. A product does not become ethically owed merely because researchers hoped it would work.
Third, arrangements must exist in advance. The ethical responsibility begins before researchers know whether the intervention will succeed.
The Declaration allows exceptions, but those exceptions must be approved by a research ethics committee. It also requires the specific post-trial provisions to be disclosed during informed consent.
“Beneficial and reasonably safe” does not mean the intervention is risk-free
No effective clinical intervention is guaranteed to be free of risk. The phrase should therefore not be interpreted as requiring absolute safety.
The trial must provide a sufficient basis for identifying the intervention as beneficial and reasonably safe in the relevant context. That judgment can depend on the evidence generated, the participant's condition, available alternatives, and the clinical significance of continued treatment.
This also means that an interim impression that “my patient seems better” is not automatically equivalent to a trial identifying an intervention as beneficial and reasonably safe.
Post-trial access does not automatically apply to every trial participant
Some participants may no longer need treatment. Some may have discontinued because of adverse effects. Others may have received placebo or a comparator. The intervention may not be clinically appropriate for everyone.
The 2024 formulation is therefore based on continuing need rather than enrollment alone.
Watch Out
Do not promise every participant automatic access to the experimental intervention after the study unless the protocol can actually support that promise. Post-trial provisions should describe what will happen under defined circumstances rather than offering a vague assurance that treatment will somehow continue.
The researcher is not necessarily expected to pay personally
The phrase “researchers owe participants continued access” can create a misleading image of the principal investigator personally buying treatment indefinitely.
That is not how the Declaration of Helsinki frames responsibility. Sponsors and researchers must arrange the provisions, but the intervention may be provided by themselves, healthcare systems, or governments.
CIOMS similarly treats continued access as a matter requiring advance agreement among relevant stakeholders. Its guidance recommends specifying the modalities of access, the parties involved in continued care, the organization responsible for payment, and the duration of provision.
Post-trial access is therefore partly an allocation-of-responsibility problem. Someone must know who will do what before the trial ends.
The duration of access may have limits
Continued access does not necessarily mean lifetime provision.
CIOMS notes that sponsors, researchers, and community members may agree before a trial begins that an intervention demonstrating significant benefit will be provided for a predetermined period. It also recognizes that direct sponsor or researcher provision may no longer be necessary once the intervention becomes available through the public health system.
Other possible transition points might depend on regulatory approval, commercial availability, availability through insurance or a health system, clinical need, or arrangements specified in the protocol.
The ethical weakness is not necessarily setting a limit. The more serious problem is leaving participants unaware of what the limit is until the intervention is withdrawn.
Post-trial access can be logistically difficult even when ethically justified
An experimental intervention may not yet have regulatory authorization for ordinary clinical use. Manufacturing may be limited. Continued administration may require specialized monitoring. A device may need maintenance. A complex intervention may depend on trained staff or facilities that disappear when research funding ends.
These constraints matter because ethical obligations need feasible implementation pathways.
They are also reasons to plan early. If continued access would require regulatory mechanisms, extension protocols, healthcare-system agreements, financing, or special supply arrangements, those problems are easier to address before participants become dependent on an intervention than on the final day of a trial.
Post-trial access should be distinguished from an open-label extension
Some participants continue receiving an intervention through an open-label extension study after the main randomized phase. That can provide continued access, but it remains research.
Participants may still undergo study procedures, provide data, meet eligibility requirements, and remain subject to a research protocol. An extension study is therefore not conceptually identical to post-trial clinical provision outside research.
Researchers should explain which arrangement is actually being offered rather than describing any continuation as though it were ordinary treatment access.
Access to study results is a separate post-trial responsibility
Post-trial access is sometimes used loosely to include anything participants receive after research. That can obscure important distinctions.
The 2024 Declaration of Helsinki separately states that participants should have the option of being informed about the general outcome and results of the research. It also requires research results to be made publicly available.
A participant may therefore have an interest in access to the knowledge produced by the study even when there is no intervention to continue.
Conversely, sending a participant the study results does not resolve the problem of continued treatment when the participant still needs the intervention.
Post-trial obligations are especially important where ordinary access is unlikely
The ethical stakes become sharper when research is conducted in a setting where participants would otherwise have little chance of accessing the intervention.
CIOMS has paid particular attention to post-trial access in resource-limited settings. Its guidance argues that sponsors may derive substantial benefits from efficiently conducted trials and that it can be reasonable to expect continued provision of proven treatment to research participants in such settings.
The issue connects directly to who bears the burdens of research and who receives its benefits. A trial can look especially troubling when participants help establish that an intervention works but lose access immediately afterward while the product becomes available to more advantaged populations.
Real protocols do not always translate ethical guidance into actual access
The gap between ethical guidance and protocol practice is not merely theoretical.
A published review of 193 clinical-trial protocols submitted to the University of the Philippines Manila research ethics board between 2012 and 2017 found that 51.81% indicated some form of post-trial access. Only 29.5% could be partially accounted for in forms identified in the relevant guidance, and none clearly provided continued access to the intervention after the trial, although some contemplated later sponsor evaluation or open-label extension.
The study was conducted on protocols from one institution and an earlier period, so it should not be treated as a current estimate for all Philippine trials. Its value is more specific: it illustrates how an ethical principle can appear in guidance while remaining vague or absent in actual protocol arrangements.
Post-trial access should not be used to justify an otherwise unethical trial
Offering continued treatment afterward cannot compensate for excessive risks, invalid consent, poor science, unfair participant selection, or an exploitative research setting.
Post-trial provisions are one component of ethical trial design, not a bargaining chip that purchases permission for other ethical weaknesses.
Similarly, promising access should not obscure the broader question of whether research in a disadvantaged community is genuinely responsive to the people carrying its burdens.
